IP Library › Granted Patent US 11,318,168
Granted Patent B2
US 11,318,168 · App. 15/631,707 · Granted May 3, 2022

Human tissue derived compositions and uses thereof

Inventors: Steven Michael Sinclair (Ellicott City, MD); Alla Danilkovitch (Columbia, MD); Malathi Sathyamoorthy (Ellicott City, MD); Jin-Qiang Kuang (Glenelg, MD); Sandeep Dhall (Elkridge, MD); Yishan Liu (Doylestown, PA); Anthony John Melchiorri (Ellicott City, MD); Matthew Robert Moorman (Chestertown, MD); Mena Schiano Lo Moriello (Silver Spring, MD); Anne Allgood Lerch (Annapolis, MD)
Assignee: OSIRIS THERAPEUTICS, INC.
A61K35/50A61K9/0014A61K9/0019A61K9/0024A61K9/06A61K9/19A61K35/33A61K35/51A61L26/0057A61L27/3604A61L27/3834A61P17/02A61P19/00A61P19/02A61P19/04A61P19/10A61P29/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,318,168
App. No.
15/631,707
Granted
May 3, 2022
Kind
B2
Abstract

Disclosed are compositions comprising a non-homogenized chorionic matrix, a homogenized amniotic matrix and a homogenized UC (UC) matrix, wherein the non-homogenized chorionic matrix comprises viable cells. Disclosed are methods of making the compositions disclosed herein comprising preparing a non-homogenized chorionic matrix, preparing a homogenized amniotic matrix, preparing a homogenized UC matrix, and combining the non-homogenized chorionic matrix, the non-homogenized chorionic matrix, and the homogenized UC matrix. Disclosed are methods of treating a tissue injury or chronic pain comprising administering any of the disclosed compositions to an area of a subject comprising a tissue injury.

Claims (12)

1. A composition comprising a non-homogenized chorionic matrix, a devitalized homogenized amniotic matrix, and a devitalized homogenized umbilical cord (UC) matrix, wherein the non-homogenized chorionic matrix comprises native cells, wherein the composition is lyophilized, and wherein at least 70% of the native cells of the non-homogenized chorionic matrix are viable after storage at room temperature in the lyophilized state, and wherein the native cells are not culturally expanded after lyophilization.

2. The of claim 1 , further comprising a viscous modifier.

3. The composition of claim 1 further comprising viable, isolated amniotic cells.

4. The composition of claim 1 , further comprising a scaffold.

5. The composition of claim 1 , wherein the homogenized amniotic matrix and/or the homogenized UC matrix are not decellularized.

6. The composition of claim 1 , wherein the non-homogenized chorionic matrix is minced.

7. The composition of claim 1 , wherein the composition comprises viable chorionic stem cells, amniotic stem cells, fibroblasts, epithelial cells or a combination thereof.

8. The composition of claim 1 , wherein the homogenized amniotic matrix and homogenized UC matrix are derived from the same donor.

9. The composition of claim 1 , wherein the nonhomogenized chorionic matrix and homogenized amniotic matrix are from the same donor.

10. The composition of claim 1 , wherein the nonhomogenized chorionic matrix and homogenized UC matrix are from the same donor.

11. The composition of claim 1 , wherein the homogenized UC matrix comprises de-veined UC tissue.

12. A pharmaceutical composition comprising the composition of claim 1 and a pharmaceutically acceptable carrier.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 6, 2020
From: SINCLAIR, STEVEN MICHAEL; DANILKOVITCH, ALLA; SATHYAMOORTHY, MALATHI; KUANG, JIN-QIANG; DHALL, SANDEEP; LIU, YISHAN; MELCHIORRI, ANTHONY JOHN; MOORMAN, MATTHEW ROBERT; SCHIANO LO MORIELLO, MENA; ALLGOOD LERCH, ANNE
To: OSIRIS THERAPEUTICS, INC.
Reel/Frame 052038/0001 →
Continuity (2)
Provisional Application 62354466 · Jun 24, 2016
Related Publication 20170368105A1 · Dec 28, 2017